 |
|
|
| |
17th International Workshop
on Clinical Pharmacology of
HIV and Hepatitis Therapy
June 8-10, 2016, Washington DC
|
| |
| |
- Pharmacokinetics, safety and efficacy of atazanavir, dolutegravir and lamivudine as maintenance regimen in HIV-infected patients: a pilot study - (08/12/16)
- Pharmacokinetics of Darunavir, Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir and Ribavirin in Adults Infected with Hepatitis C Virus (HCV) Genotype 1 and Human Immunodeficiency Virus (HIV) - (06/29/16)
- Identification and Management of Drug-Drug Interactions (DDIs) by a Clinical Pharmacist in Patients Prescribed Hepatitis C Virus (HCV) Treatment - (06/29/16)
- Population Pharmacokinetic Analysis of
Velpatasvir, a Pangenotypic HCV NS5A Inhibitor,
in Healthy and Hepatitis C Virus-Infected Subjects - (06/29/16)
- Evaluation of Transporter and Cytochrome P450-Mediated Drug-Drug Interactions with the Pan Genotypic HCV NS3/4A Protease Inhibitor Voxilaprevir (GS-9857) or Sofosbuvir/Velpatasvir/Voxilaprevir and Phenotypic Probe Drugs - (06/29/16)
- The 17th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy Report by Courtney Fletcher, PharmD/Jennifer Kiser, PharmD - (06/27/16)
- Development of Dolutegravir Combination Nanoparticle Fabrications for HIV Prophylaxis - (06/23/16)
- In Silico Pharmacokinetic/Pharmacodynamic Simulation Of Long Acting Tenofovir Injectable Formulation For Pre-exposure Prophylaxis Strategies - (06/22/16)
- No Clinically Significant Interaction of MK-3682 With the HIV Medications Dolutegravir, Raltegravir, Rilpivirine, and Tenofovir Disoproxil Fumarate - (06/17/16)
- No Clinically Significant Interaction of MK-8408 With the HIV Medications Dolutegravir, Raltegravir, Rilpivirine, and Tenofovir Disoproxil Fumarate - (06/16/16)
- Efficacy of once-weekly MK-8591 in SIV infected rhesus macaques - (06/17/16)
- Rifampin (RIF) Decreases Cabotegravir (CAB) Exposure following Oral Coadministration - (06/17/16)
- Pharmacokinetics and Exploratory Interactions of HIV Maturation Inhibitor BMS-955176 in Healthy Subjects: Single- and Multiple-Ascending Dose Studies - (06/17/16)
- Open-Label, Drug-Drug Interaction Study between Second-generation HIV-1 Maturation Inhibitor BMS-955176 and Tenofovir in Healthy Subjects - (06/17/16)
- Open-Label, Drug-Drug Interaction Study between HIV-1 Attachment Inhibitor BMS-663068 and Maraviroc in Healthy Subjects - (06/17/16)
- Pharmacokinetics, safety and efficacy of atazanavir, dolutegravir and lamivudine as maintenance regimen in HIV-infected patients: a pilot study - (06/17/16)
- MK-3682, a HCV NS5B Inhibitor with a Broad Spectrum of HCV Genotypic Activity, Demonstrates Potent Antiviral Activity in Genotypes -1,-2, and -3 HCV-Infected Patients - (06/16/16)
- Coadministration of ZEPATIER™ (Grazoprevir/Elbasvir) With Tenofovir Disoproxil Fumarate Resulted in No Clinically Meaningful Drug-Drug Interaction in Healthy Subjects - (06/16/16)
- Cabotegravir Long-Acting (LA) Injectable Nanosuspension - (06/16/16)
- Lack of an Effect of Ledipasvir on CYP3A Activity in Healthy Volunteers - (06/16/16)
- Population Pharmacokinetic Analysis of Velpatasvir, a Pangenotypic HCV NS5A Inhibitor,in Healthy and Hepatitis C Virus-Infected Subjects - (06/16/16)
- Lack of Pharmacokinetic Interaction Between Emtricitabine/Tenofovir Alafenamide and Oral Contraceptive Ethinyl Estradiol/Norgestimate - (06/16/16)
- Lack of Clinically Relevant Effect of Food on the Pharmacokinetics of Tenofovir Alafenamide - (06/16/16)
- Pharmacokinetics of Dolutegravir After Switching to Abacavir/Dolutegravir/ Lamivudine From an Efavirenz-Based Regimen: A PK Sub-Study From STRIIVING - (06/16/16)
- A CLINICALLY MEANINGFUL DRUG-DRUG INTERACTION OBSERVED BETWEEN ZEPATIERTM (GRAZOPREVIR/ELBASVIR) AND STRIBILD® HIV FIXED-DOSE COMBINATION IN HEALTHY SUBJECTS - (06/14/16)
- Pharmacokinetic Interaction Between Emtricitabine/ Tenofovir Alafenamide and Boosted Atazanavir - (06/14/16)
- Efficacy of once-weekly MK-8591 in SIV infected rhesus macaques - (06/14/16)
- Targeting Tissue Drug Concentrations for HIV Prevention - What do we know? - (06/14/16)
- Raltegravir (RAL) Pharmacokinetics (PK) and Safety in HIV-1 Exposed Neonates at High Risk of Infection (IMPAACT P1110) - (06/14/16)
- Clinical, biological and Pharmacological relevance of Ledipasvir/Sofosbuvir drug interaction with TDF containing Regimen in HCV/HIV co-infected patients. - (06/14/16)
- LEDIPASVIR/SOFOSBUVIR and TENOFOVIR in HIV-HCV co-infected PATIENTS: IMPACT on TENOFOVIR Ctrough and RENAL SAFETY - (06/14/16)
- NS5B HCV Inhibitor Strong in 7-Day Monotherapy Trial - Mark Mascolini - (06/13/16)
- High risk on drug-drug interactions during hepatitis C treatment: a nationwide cohort - (06/13/16)
- Phosphoramidate prodrugs of uridine analogs, including sofosbuvir, are metabolized to both uridine and cytidine triphosphates in Huh7 cells and primary human hepatocytes - (06/13/16)
- High risk on drug-drug interactions during hepatitis C treatment: a nationwide cohort - (06/13/16)
- Rilpivirine Half-Life Lower in Real-World Cohort Than Phase 3 Trials - Mark Mascolini - (06/13/16)
- Simulations See Protection From HIV With Long-Acting Injectable Tenofovir - Mark Mascolini - (06/13/16)
- Grazoprevir and Elbasvir Levels 5- and 2-Fold Higher With Stribild - Mark Mascolini - (06/13/16)
- Tenofovir Levels in Red Blood Cells Jump 4-Fold With Sofosbuvir/Ribavirin - Mark Mascolini - (06/13/16)
- Increased Tenofovir Diphosphate in Cells, but Not Tenofovir in Plasma, with Sofosbuvir and Ribavirin - (06/10/16)
- Evaluation of Drug-Drug Interaction Between Sofosbuvir/Velpatasvir and Rifaximin in HCV-Infected Subjects with Moderate Hepatic Impairment - (06/10/16)
- Effect of daclatasvir/asunaprevir/beclabuvir in fixed-dose combination on the pharmacokinetics of CYP450/ transporter substrates in healthy subjects - (06/10/16)
- HIV RNA and DNA in GALT Similar With Raltegravir and Dolutegravir - Mark Mascolini - (06/10/16)
- Ribavirin Levels Too High or Low in Most Patients Taking DAAs - Mark Mascolini - (06/10/16)
- Over Half of Netherlands Patients Starting DAAs Risk Drug-Drug Interaction - Mark Mascolini - (06/10/16)
- Virologic and Immunologic Responses to Raltegravir and Dolutegravir in GALT of HIV+ Men and Women - (06/10/16)
- Cumulative tenofovir exposure is associated with decreased BMD in young and old HIV-infected adults on tenofovir based regimens - (06/10/16)
- Pharmacokinetic, Safety and Efficacy of Darunavir/Ritonavir in HIV+ Pregnant Women** - (06/10/16)
- Cumulative Tenofovir Level Tied to Lower Spine BMD in Young Adults - written by Mark Mascolini - (06/8/16)
- Pharmacokinetic, Safety and Efficacy of
Darunavir/Ritonavir in HIV+ Pregnant Women - (06/8/16)
- Darunavir Troughs Lower in Trimesters 2 and 3 With Once-Daily Dosing - written by Mark Mascolini - (05/29/16)
|
|
| |
|
|
|
|
|
|
